Skip to main content
. Author manuscript; available in PMC: 2014 Feb 1.
Published in final edited form as: Lancet Neurol. 2013 Jan 3;12(2):157–165. doi: 10.1016/S1474-4422(12)70310-1

Table 1.

Number and severity of symptoms during the first month of the disease

(n = 571)# Non-tumor Tumor All
number of symptoms * 8 28 8% 24 11% 52 9% 0·37 **
7 64 18% 48 22% 112 20%
6 72 20% 52 24% 124 22%
5 70 20% 37 17% 107 19%
4 72 20% 31 14% 103 18%
3 34 10% 13 6% 47 8%
2 10 3% 10 5% 20 4%
1 5 1% 1 0% 6 1%
maximum mRS 5 296 84% 199 91% 495 87% 0·086
4 49 14% 19 9% 68 12%
3 6 2% 1 0% 7 1%
Unknown 1 0 1
ICU Yes 248 71% 187 85% 435 77% < 0·0001
No 100 29% 32 15% 132 23%
Unknown 4 4 4
#

Clinical information was insufficiently detailed in six patients.

*

The eight symptom categories are: behavior/cognition, memory dysfunction, speech disorder/mutism, seizures, decrease in level of consciousness, movement disorder, autonomic dysfunction and central hypoventilation.

**

Fisher Exact test: 1-3 vs 4-8 symptoms, comparing non-tumor and tumor patients.

Fisher-Freeman-Halton test

Fisher Exact test

mRS = modified Rankin Scale; ICU = intensive care unit

HHS Vulnerability Disclosure